Englewood Lab (950140) Q1 2025 earnings summary

Executive summary

• Operates as a cosmetics ODM/OEM manufacturer in the US, specializing in skincare, functional, and color cosmetics, with a strong R&D focus and global certifications.

• Main subsidiary is Englewood Lab Korea, fully owned and consolidated, with no changes in subsidiary structure during the period.

• Listed on KOSDAQ since 2016, with stable management and no significant changes in capital stock or major shareholders.

Financial highlights

• Q1 2025 consolidated revenue: $29.28M, down from $39.58M in Q1 2024.

• Q1 2025 operating income: $3.15M, net income: $2.23M, both lower than Q1 2024 ($4.99M and $4.98M, respectively).

• Gross margin for Q1 2025: $6.59M, down from $8.44M in Q1 2024.

• Cash and cash equivalents increased to $25.77M at Q1 2025 end, up from $19.14M at 2024 year-end.

• Basic EPS for Q1 2025: $0.11, compared to $0.25 in Q1 2024.

Outlook and guidance

• Focus on expanding into premium skincare markets and targeting global top-tier brands.

• Continued investment in R&D and regulatory compliance to maintain competitive edge.